Becton, Dickinson and Company (BDX) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $148.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 7 days (event risk).
Becton, Dickinson and Company is a global medical technology company developing and selling medical supplies, devices, lab equipment, and diagnostics across BD Medical, BD Life Sciences, and BD Interventional segments. Sells to hospitals, clinics, labs, and pharma companies... Read more
Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $148.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 7 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-09Item 5.02MEDIUMRichard E. Byrd, Executive Vice President and President of the Interventional segment, departed effective April 6, 2026. No successor named in the available body text.SEC filing →
- 2026-02-09Item 1.01HIGHBD completed the spin-off of Biosciences and Diagnostic Solutions and combination with Waters Corporation on February 9, 2026. BD shareholders expected to own ~39.2% of the combined company; BD received ~$4B cash distribution. Major structural change.SEC filing →
- 2026-01-30Item 5.02LOWBoard approved amendments to Employee Stock Investment Plan (adding 5M shares) and 2002 Universal Stock Incentive Plan (adding 25M shares) at January 27, 2026 meeting. Routine compensatory arrangement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.3/10 is below the 5.0 floor at $148.05 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; Earnings in 7 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $141.62. Score 5.4/10, moderate confidence.
Take-profit target: $166.57 (+12.5% upside). Prior stop was $141.62. Stop-loss: $141.62.
Earnings in 7 days (event risk); Negative momentum.
Becton, Dickinson and Company trades at a P/E of 23.7 (forward 10.8). TrendMatrix value score: 7.0/10. Verdict: Sell.
20 analysts cover BDX with a consensus score of 3.7/5. Average price target: $191.
What does Becton, Dickinson and Company do?Becton, Dickinson and Company is a global medical technology company developing and selling medical supplies, devices,...
Becton, Dickinson and Company is a global medical technology company developing and selling medical supplies, devices, lab equipment, and diagnostics across BD Medical, BD Life Sciences, and BD Interventional segments. Sells to hospitals, clinics, labs, and pharma companies worldwide; completed spin-off combination of its Biosciences and Diagnostic Solutions business with Waters Corporation in February 2026.